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Nonrandomized trials of postmenopausal estrogen replace- 
ment have shown a benefit in the prevention of coronary artery 
disease. Less clear are the specific mechanisms by which this 
occurs. Estrogen has beneficial effects on the lipid profile, with 
significant elevations in high density lipoprotein cholesterol and 
reductions in low density lipoprotein cholesterol reported. Also, 
antioxidant properties have been ascribed to estrogen. In addi- 
tion, estrogen has been shown to prevent paradoxic vasoconstric- 
tion in atherosclerotic coronary arteries after acetylcholine and 
may have calcium channel-blocking and alpha2-inhibiting prop- 
erties. Other proposed mechanisms of cardiovascular protection 
include reductions in serum fibrinogen and increases in prosta- 
cyclin biosynthesis. There is some evidence that cardiovascular 
biomechanics may be mildly depressed after menopause and that 
estrogen may normalize these changes by increasing ventricular 
contractility and, possibly, relaxation. Far less is known about the 
cardiovascular effects of progesterone, but overall it does not 
appear that the less androgenic progestins ubstantially modify 
the effects of estrogen. Because more women >50 years old die of 
cardiovascular disease than any other cause, further clinical 
investigations of the risks and benefits of estrogen replacement 
and combined estrogen and progesterone therapy are clearly 
needed. 
(J Am Coil Cardiol 1995;26:1403-10) 
Only a decade ago, considerable controversy surrounded the 
issue of exogenous estrogen use for the prevention of coronary 
artery disease in postmenopausal women (1). Although con- 
clusive data are not yet available, since the mid-1980s there has 
been increasing epidemiologic evidence that postmenopausal 
estrogen replacement therapy in conventional doses (Table 1) 
may reduce the relative risk of cardiovascular disease to 0.37 to 
0.79 (2-6) and improve survival in women with documented 
coronary artery disease (7). Furthermore, most studies have 
shown either no change or a decrease inthe incidence of stroke 
(1,2,5,6,8-10) and a reduction in all-cause mortality (5,6). 
The mechanism by which exogenous estrogen may prevent 
cardiovascular disease after menopause is most likely multifac- 
torial (Table 2). Estrogen replacement exerts salutary effects 
on the lipid profile. However, it appears that estrogen's effects 
on lipids account for only 25% to 50% of the observed 
reduction in cardiovascular risk (2,3,11). Moreover, estrogen 
has a number of other properties that may result in cardiovas- 
cular protection. For instance, estrogen appears to potentiate 
endothelium-derived relaxing factor in coronary arteries; a 
considerable body of data now suggest hat this effect may be 
as important as the effect on lipid metabolism. Estrogen may 
also reduce circulating fibrinogen. In addition, characteristics 
similar to calcium channel blocking agents and aipha2- 
inhibitors have been ascribed to estrogen, as has a role in 
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increasing intravascular prostacyclin production. Overall, es- 
trogen replacement may result in a mild reduction in systemic 
vascular esistance while slightly increasing ventricular ino- 
tropy. This review focuses on these and other mechanisms by 
which estrogen affects the cardiovascular system and the 
potential clinical implications of postmenopausal hormone 
replacement. 
Ef fects  o f  Es t rogen on  L ip id  Metabo l i sm 
Clinically, attention has been focused on the impact of 
estrogen and progesterone on the lipid profile (Table 3). 
Estrogen use is associated with elevations in high density 
lipoprotein (HDL) cholesterol, especially HDL2, by up to 20% 
(2,3,8,12-16) and reductions in low density lipoprotein (LDL) 
cholesterol by up to 19% (2,12,14,16). Lipoprotein(a) de- 
creases by at least 13% (16), and apolipoprotein A-I increases 
by 13% to 22% (12,13,16). In addition, serum triglyceride 
levels are elevated by 16% to 42% (2,12,16). Although a mild 
reduction in total apolipoprotein B levels has been reported 
(13), large very low density (VLDL) apolipoprotein B levels 
increase by -30% (12). The mechanism appears to be in- 
creased production rather than decreased clearance. Oral 
estrogens appear to have effects on VLDL and LDL choles- 
terol, but transdermal estrogens do not; and although HDL2 
levels increase with transdermal estrogen, they do not increase 
to the extent seen with oral estrogen replacement. This effect 
has been postulated to be due to supraphysiologic concentra- 
tions of estrogen in the portal circulation after intestinal 
absorption, leading to alterations in hepatic metabolism of 
lipids (12). 
When progestins were added to estrogen to reduce the risk 
of endometrial cancer in women with intact uteri, it was 
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Table 1. Postmenopausal Estrogen Replacement: Commonly Used Formulations 
Trade Name Company Drug Dosage Range Route 
Estrace Mead-Johnson 17-beta-estradiol 1-2 mg Oral 
Estraderm CIBA 17-beta-estradiol 0.05-0.1 mg/day Dermal patch 
Estratab Solvay Esterified estrogens 0.3-2.5 mg Oral 
Estrovis Parke-Davis Quinestrol 100/xg Oral 
Ogen Abbott Estropipate 0.75-6 mg Oral 
Premarin Wyeth-Ayers Conjugated estrogen 0.3-2.5 mg Oral 
TACE Marion-Merrell-Dow Chlorotrianisene 12-25 mg Oral 
initially believed that the lipid profile would be adversely 
affected and perhaps negate the beneficial effect of estrogens. 
However, it has been determined that different progestins may 
exert variable effects on HDL levels. The more androgenic 
progestins (levonorgestrel and norethinone) have been found 
to lower HDL levels, but the less androgenic medroxyproges- 
terone appears to have a smaller effect (15,17). Although the 
Framingham Offspring Cohort Study (13) found no change in 
LDL levels with oral estrogen only, a significant reduction in 
LDL was found in combined therapy with estrogen and 
medroxyprogesterone. The combination therapy was also as- 
sociated with a similar elevation in HDL levels; no change in 
triglyceride, VLDL or apolipoprotein B levels; and a small but 
significant increase in apolipoprotein A-I levels (13). Soma et 
al. (18) found a 50% reduction in lipoprotein(a) with the 
combination therapy, a 30% reduction in LDL and a 19% 
increase in HDL (18). Similar findings were reported in a 
recent study by Nabulsi et al. (16) in which the elevations in 
HDL, HDL2, HDL 3 and apolipoprotein A-I and the reduc- 
tions in LDL, apolipoprotein B and lipoprotein(a) were similar 
between estrogen and combined estrogen and progesterone. 
To address these issues objectively, the Postmenopausal 
Estrogen/Progestin Interventions (PEPI) trial (19), a random- 
ized, controlled trial of conjugated estrogen with and without 
the addition of progesterone (medroxyprogesterone r mi- 
cronized progesterone) was undertaken. This 3-year study of 
875 postmenopausal women found significant elevations in 
total HDL cholesterol with all regimens, although the combi- 
nation therapy significantly attenuated this increase. The aver- 
age increase in HDL levels was 5.6 mg/dl in the estrogen group 
and 1.2 to 4.1 mg/dl in the progesterone groups. The HDL 
subtypes were not evaluated. The LDL cholesterol was low- 
ered to the same degree in all active treatment groups (14.5 to 
17.7 mg/dl). The increase in triglyceride levels (11.4 to 13.7 
mg/dl) did not differ significantly between estrogen and com- 
bination therapy (19). 
It should be noted that in women 50 to 69 years old with 
triglyceride levels of 200 to 399 mg/dl, the Lipid Research 
Clinics Follow-up Study (20) reported that the relative risk of 
cardiovascular disease mortality when controlled for multiple 
factors, including estrogen use, was 1.65. More significantly, at 
triglyceride levels ->400 mg/dl, the relative risk was 3.44. An 
HDL level <50 mg/dl was associated with a relative risk of 
1.74; the combination of HDL ->50 mg/di appeared to signif- 
icantly attenuate the risk of hypertriglyceridemia (20). It is 
possible, therefore, that the estrogen-induced increase in HDL 
cholesterol may attenuate the risk of modestly increased 
triglyceride levels in women treated with estrogen replace- 
ment, but there are little data regarding the relative benefits of 
estrogen replacement when adjusted for triglyceride levels. 
In addition to lowering lipid levels, estrogen (but not 
progesterone or testosterone) also demonstrates marked anti- 
oxidant properties. At high local concentrations, 17-beta- 
estradiol has been found to inhibit LDL oxidation and reduce 
cholesterol ester formation in in vitro preparations (21-24), 
whereas testosterone does not (24). Increased cellular resis- 
tance to the cytotoxic effects of oxidized LDL has also been 
demonstrated in vitro; the mechanism of this effect is as yet 
unknown (21). As the role of antioxidants in coronary artery 
disease is studied, this property of estrogen may become 
clarified. 
Effects of Estrogen on Hemostatic Factors 
Elevations in plasma concentrations of fibrinogen and 
factor VII have been associated with an increased incidence of 
Table 2. Estrogen: Proposed Mechanisms of 
Cardiovascular Protection 
Beneficial alteration of lipid profile 
Antioxidant effect 
Reduction of serum fibrinogen 
Inhibition of myointimal hyperplasia 
Inhibition of smooth muscle cell collagen biosynthesis 
Potentiation of endothelinm-derived r laxing factor 
Calcium-channel blocking effect 
Alpha2-inhibition 
Increased prostacyclin biosynthesis 
Table 3. Estrogen and Lipid Metabolism 
Increases 
HDL cholesterol (including HDL 2 and HDL3) 
Apolipoprotein A-I 





HDL = high density lipoprotein; LDL = low density lipoprotein; VLDL = 
very low density lipoprotein. 
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Table 4. Estrogen: Effects on Cardiovascular System in Animal Studies 
Ref. 
No. Estrogen Dose Duration Concentration* Effect Species 
35 17-beta-estradiol NA 14 day 10-6_10 12 mol/liter Decreased aortic smooth muscle cell collagen Bovine cell culture (gender 
36 17-beta-estradiol 3 wk NA 
37 Estradiol cipionate 3 wk 30-14,703 pg/ml 
biosynthesis 
Decreased aortic collagen and elastin 
Prevention of cylosporin-induced aortic foam 







Rabbit (male and female) 
38 17-beta-estradiol NA 25 mo 221 ± 22 pg/ml Reduction in extent of coronary Ovariectomized monkey 
atherosclerosis 
39 17-beta-estradiol 54 ng Acute 312 pg/ml Potentiation of endothelium-dependent Ovariectomized monkey 
vasodilation i atherosclerotic coronary 
arteries 
40 17-beta-estradiol NA 26 mo 243 ± 30 pg/ml Potentiation of endothelium-dependent Ovariectomized monkey 
vasodilation i atherosclerotic coronary 
arteries 
80 Estradiol benzoate 4/zg/day 4 days NA Increase in cardiac beta-adrenergic re eptors, Ovariectomized rats 
in conjunction with progesterone 
80 Estradiol benzoate 4 ~g/day Acute NA Increase in cardiac muscarinic receptor Ovariectomized rats 
density, in conjunction with progesterone 
46 4-hydroxylated estradiol NA Acute 3.5 _+ 10 5 mol/liter Calcium channel-blocking effect Pig (female) 
47 17-beta-estradiol NA Acute 10 -6 mol/liter Calcium channel-blocking effect Guinea pig (male) 
45 17-beta-estradiol NA Acute 10 7-10 5 mol/liter Calcium channel-blocking effect Rabbit (male and female) 
48 17-beta-estradiol 100/zg/day 4 days 64.3 + 17.4 pg/ml Alpha2-inhibition Ovariectomized rabbit 
49 17-beta-estradiol 1/~g/kg Acute NA Enhanced alpha-adrenergic activation Ovariectomized sheep 
50 17-beta-estradiol 1/zg/kg Acute NA Enhanced alpha-adrenergic activation Ovariectomized sheep 
57 17-beta-estradiol NA Acute >10 _7 mol/liter Reversal of vasopressin-mediated coronary Rat (male and female) 
spasm 
Increased aortic prostaeyclin 59 Endogenous estradiol from NA 5 days 152 pg/ml Rat cell culture (male) 
calf serum 
*Normal midcycle premenopausal estrogen level 60 to 260 pg/ml or 2.1 x 10 -1° to 9.1 X 10 xo mol/liter; normal postmenopausal estrogen level 0 to 45 pg/ml or 
0 to 1.8 x 10 lO mol/liter. NA = not available or not applicable; Ref. = reference. 
coronary artery disease (25). The use of estrogen (14,19) or 
combined estrogen and progesterone (16,19) in postmeno- 
pausal women has been associated with lower levels of fibrin- 
ogen. Although estrogen alone increases factor VII concentra- 
tion, the addition of progestin ormalizes these levels (16). 
Triglycerides are thought o increase factor VII activity in men 
by an increase in activated phospholipase C-sensitive factor 
VII complexes (26), suggesting that the increase in triglyceride 
levels seen with estrogen may be responsible for the increase in 
factor VII levels. A 12% to 26% reduction from baseline levels 
of factor VII with combination therapy was found in an earlier 
study (27) that used higher dose 17-beta-estradiol (2 mg/day), 
in which the highest dose of the progestin norethisterone 
acetate used (1 mg) was associated with the greatest decline in 
factor VII. 
Because the reported changes in the coagulation profile are 
small, it is not surprising that in a case-control study of women 
>45 years old (28), no evidence of increased risk of venous 
thrombosis was found in those treated with postmenopausal 
estrogen replacement. Nevertheless, it would be prudent o 
weigh carefully the potential risks of thrombosis in a woman 
with a hypercoagulable disorder. 
The Cardiovascular System as a Target 
Tissue for Estrogen 
Estrogen receptors have been discovered in the cardiovas- 
cular systems of baboons (29), rats (30,31) and humans (32,33), 
and progesterone r ceptors have been identified in the human 
heart and great vessels (34). There are animal data supporting 
the hypothesis that the cardiovascular system is an estrogen 
target issue and that estrogen may play a significant role in 
regulating cardiovascular cell function (30). This concept is 
also suggested by the finding, at autopsy, of reduced estrogen 
receptors in smooth muscle cells of atherosclerotic coronary 
arteries of premenopausal women compared with those with 
no atherosclerosis (32). In the baboon, localization of estrogen 
receptors appears to be distinctly different from that of testos- 
terone receptors (31). 
Animal studies (35-37) have shown that vascular smooth 
muscle cell hyperplasia nd collagen biosynthesis are reduced 
by estrogen administration (Table 4). In patients, postmeno- 
pausal estrogen use has been associated with borderline sig- 
nificant reductions in common carotid artery wall thickness 
compared with those who have never used estrogen and with 
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Table 5. Estrogen: Effects on Cardiovascular System in Postmenopausal Women 
Ref. No. Estrogen Dose Duration Concentration* Effect 
41 Ethinyl estradiol 35 tzg Short term NA 
42 17-beta-estradiol NA Short term 282 - 121 pg/ml 
43 17-beta-estradiol NA Short term 318 _+ 188 pg/ml 
41 Ethinyl estradiol 35 p,g Short term NA 
Potentiation of endothelium-dependent vasodilation in atherosclerotic 
coronary arteries 
Potentiation of endothelium-dependent vasodilation i atherosclerotic 
coronary arteries 
Potentiation of endothelium-independent vasodilator responses 
Increased coronary blood flow, decreased coronary resistance, 
increased coronary cross-sectional rea 
*Normal midcycle premenopausal estrogen level 60 to 260 pg/ml or 2.1 x 10 Jo to 9.1 x 10 ~o mol/liter; normal postmenopausal estrogen level 0 to 45 pg/ml or 
0 to 1.8 x 10 ~o mol/liter. Abbreviations as in Table 4. 
a reduction in the incidence of subclinical carotid stenosis 
(14). 
On the basis of encouraging data (38-40) that both short- 
and long-term estrogen administration improves cardiovascu- 
lar endothelial cell-mediated vasodilation in ovariectomized 
monkeys fed an atherogenic diet, a study (41) was performed 
in postmenopausal women referred for cardiac atheterization. 
Coronary flow, resistance and cross-sectional rea were mea- 
sured before and after administration of 35/~g of intravenous 
ethinyl estradiol (a dose found in many oral contraceptive 
pills). No acute change was found in blood pressure or heart 
rate at this dose, yet coronary blood flow increased by 23%, 
coronary resistance decreased by 15%, and cross-sectional area 
increased by 20%. In those women in whom the coronary 
arteries appeared free of lumen irregularities, aeetylcholine 
produced an increase in coronary flow and a decrease in 
resistance that were similar before and after the addition of 
estrogen. However, in those arteries with minor irregularities, 
an initial paradoxic response was seen with acetyleholine that 
was significantly attenuated by the addition of ethinyl estradiol. 
Nitroglycerin produced asimilar degree of vasodilation i both 
groups, suggesting that smooth muscle cell vasodilator capacity 
was similar (41) (Table 5). 
Another study (42) using lower intracoronary doses of 
17-beta-estradiol calculated to achieve physiologic premeno- 
pausal concentrations acutely, reported a potentiation of the 
response to acetylcholine in women referred for cardiac cath- 
eterization. Specifically, the addition of estradiol was associ- 
ated with a reversal of the vasoconstrictive response to acetyl- 
choline and an augmentation of the decrease in coronary 
resistance but did not exert an independent effect. Endotheli- 
urn-independent vascular responses were unaffected. These 
findings again suggested an endothelium-dependent effect of 
estrogen, which was present at both the large epicardial vessel 
and small intramyocardial vessel level (42). Data regarding the 
effects of long-term estrogen administration on coronary en- 
dothelial cell function are not yet available; however, Williams 
et al. (40) have shown a beneficial effect in ovariectomized 
monkeys treated with hormone replacement for 26 months. 
Although estrogen appears to potentiate endothelium- 
dependent mechanisms in the coronary vasculature, it may also 
work through endothelium-independent mechanisms in the 
periphery. This may be particularly true in postmenopausal 
women at risk for atherosclerosis. Gilligan et al. (43) found 
that in this group, estradiol potentiated both endothelium- 
dependent (acetylcholine) and endothelium-independent (so- 
dium nitroprusside) vasodilator esponses in the forearm; 
estrogen itself had no independent vasodilating effect. 
Sarrel et al. (44) recently demonstrated that in postmeno- 
pausal women with normal coronary arteries and clinical 
evidence of syndrome X, vasodilator reserve appeared to be 
diminished, as determined by a poor hyperemic response to 
occlusion of forearm blood flow. Two months after estrogen 
replacement was initiated, the hyperemic response became 
normal, and 19 of 20 patients had either marked improvement 
or resolution of chest pain. Sarrel et al. (44) noted that the 
hyperemic response is thought to reflect vasorelaxation i - 
duced by endothelium-derived relaxing factor (EDRF) and 
that the lack of this response suggests diminished vasodilator 
capacity. Because of the marked improvement in anginal 
symptoms, it was suggested that this impaired vasodilatory 
response to an endothelium-derived r laxing factor stimulus 
may be systemic, including the coronary arteries, in this group 
of estrogen-deficient women and that reversal may be effected 
by estrogen. 
Several other cardiovascular mechanisms of estrogen have 
been proposed. One explanation for the observed vasodilatory 
effects of estrogen, a calcium channel blocker-like ffect, has 
been postulated by some investigators on the basis of animal 
studies (45-47). Another potential mechanism suggested by 
short-term animal studies (48) is that estrogen may have an 
inhibitory effect on alpha2-adrenergic responses of vascular 
smooth muscle. However, short-term estrogen administration 
may enhance alpha-adrenergic a tivation, probably as a reflex 
mechanism to maintain mean arterial pressure (49,50). Estro- 
gen's interactions with the renin-angiotensin axis and pituitary 
vasopressin are not yet well defined (50-57). 
Estrogen may also mediate vasodilation through prostacy- 
clin production. Uterine arteries from postmenopausal women 
have reduced prostacyclin production compared with pre- 
menopausal rteries, yet short-term administration ofestradiol 
in vitro does not result in a significant increase in arterial 
prostacyclin production (58). However, in cultured rat aortic 
smooth muscle cells, 5 days of estradiol at physiologic oncen- 
trations resulted in marked prostacyclin biosynthesis (59). 
Because prostacyclin is known to be a potent inhibitor of 
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platelet aggregation as well as a significant vasodilator, an 
estrogen-mediated increase in prostacyclin biosynthesis may 
further explain the cardioprotective effect of estrogen replace- 
ment herapy. 
Thus, the effects of 17-beta-estradiol on the cardiovascular 
system appear to be widespread and to involve multiple 
mechanisms such as potentiation of endothelium-derived r - 
laxing factor, a calcium channel blocker effect, inhibition of the 
alpha2-adrenergic response of vascular smooth muscle, and 
increased prostacyclin biosynthesis. The relative importance of
each of these components in physiologic postmenopausal 
estrogen replacement therapy in humans remains to be eluci- 
dated, but current work suggests that estrogen's role in 
endotbelium-dependent vasodilatory mechanisms i signifi- 
cant. 
Hemodynamic Effects of Estrogen 
Animal studies. Probably as a combined effect of the 
mechanisms previously discussed, estrogens have been found 
to have significant short- and long-term hemodynamic effects 
in animal studies. During short-term estrogen treatment, car- 
diac output is increased predominantly through increases in 
heart rate, probably through a reflex-mediated response to 
systemic vasodilation (60-62). However, during long-term 
treatment, cardiac output appears to be augmented through 
elevation of stroke volume (63,64). There is evidence that after 
gonadectomy, cardiovascular biomechanics may be deranged, 
with reductions in calcium myosin adenosine triphosphatase 
(ATPase) and V-1 myosin isoenzymes associated with de- 
pressed fractional shortening and rate of circumferential short- 
ening. However, with long-term estrogen treatment these 
effects are abrogated (64). 
Studies in humans. A small number of studies have exam- 
ined the effects of estrogen on systemic hemodynamic variables 
in nonpregnant women. In premenopausal women undergoing 
ovulation induction, high serum estradiol levels were associ- 
ated with significant increases in left ventricular end-diastolic 
diameter, stroke volume and cardiac index (65). However, 
heart rate, fractional shortening and blood pressure did not 
change, and calculated systemic vascular resistance decreased. 
These hemodynamic responses to estrogens occurred within 6 
days and are most likely related to changes in intravascular 
volume (65). In a Finnish study (66), normotensive postmeno- 
pausal women placed on relatively high dose estrogen (2 to 
4 mg of 17-beta-estradiol/day) demonstrated mild reductions 
in systolic and diastolic blood pressure and mild decreases in
heart rate after 28 days. Blood volume increased by nearly 300 
ml and stroke volume by 7 to 12 ml, whereas ystemic vascular 
resistance decreased (66). 
More recent studies (16,19) of long-term estrogen replace- 
ment have not shown an effect on blood pressure. The addition 
of progesterone may result in a reduction in blood pressure 
(67,68), although this was not borne out by the PEPI trial (19). 
A systemic effect of estrogen on vascular esistance is 
suggested by a study (69) of postmenopausal women receiving 
transdermal estradiol, in whom measures of carotid artery 
impedance were followed. Impedence was elevated at baseline 
but decreased significantly by 9 weeks of estrogen therapy and 
remained below baseline for the 22-week duration of the study 
(69). 
The effect of estrogen replacement therapy on vasodilation 
and contractility has been examined in a series of studies 
(70-72) characterizing aortic flow in postmenopausal women. 
Although there was no significant change in echocardiographic 
measurements of end-diastolic and end-systolic dimensions, 
significant decreases in rest Doppler measurements of left 
ventricular contractility were compared with those in premeno- 
pausal women. These variables appeared to decline progres- 
sively over the years after menopause in women not treated 
with hormone replacement therapy (70). After 2.5 months of 
hormone replacement with estrogen and progesterone, signif- 
icant increases in Doppler measurements were found (71), 
consistent with an increase in stroke volume and contractility 
and suggesting a positive inotropic effect of estrogen. After 1 
year of hormone replacement, indexes of vasodilation had 
returned toward baseline, but the positive inotropic effects of 
estrogen appeared to persist (72). In view of the study by 
Scheuer et al. (64) demonstrating reduced calcium myosin 
ATPase activity and decreased fractional shortening in isolated 
rat hearts after gonadectomy, this study provides additional 
evidence for an inotropic effect of estrogen. 
Also consistent with a "normalizing" effect of estrogen on 
cardiovascular mechanics were the findings reported by Mano- 
lio et al. (14) of altered Doppler mitral flow velocity variables 
in postmenopausal women receiving hormone replacement 
compared with those who had never used hormones, uggest- 
ing an improvement or normalization of left ventricular dia- 
stolic function. 
Summary. Postmenopausal hormone replacement appears 
to result in small but measurable h modynamic changes. Both 
estrogen and progesterone may produce a mild lowering of 
systemic blood pressure. In addition, women treated with 
postmenopausal estrogen replacement demonstrate an in- 
crease in stroke volume and a reduction in systemic vascular 
resistance, consistent with findings from animal studies. Estro- 
gen may also exert a positive inotropic effect, possibly by 
improving cardiovascular biomechanics. 
Effects of Estrogen on Exercise Performance 
Despite evidence of significant hemodynamic changes with 
postmenopausal estrogen and combined estrogen and proges- 
terone, very few studies have investigated the effects of estro- 
gen and progesterone on exercise performance. An exercise 
electrocardiographic (ECG) study (73) found no significant 
changes in ECG responses to exercise in postmenopausal 
women receiving estrogen; however, exercise times were not 
reported. Cauley et al. (74) reported a higher grip strength in 
postmenopausal estrogen users than in nonusers in univariate 
analysis, but after multivariate analysis, estrogen replacement 
therapy was no longer an independent determinant. 
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In an exercise study (75) evaluating the effects of estrogen 
therapy in postmenopausal women with known coronary artery 
disease, sublingual 17-beta-estradiol increased time to 1 mm 
ST segment depression and prolonged total exercise time, 
suggesting an acute coronary or peripheral vasodilatory effect, 
or both. Although not significantly different, there was a trend 
toward an increase in heart rate and decreased blood pressure 
at rest (75). However, as noted previously, the short- and 
long-term effects of estrogen appear to differ significantly, and 
it is not known whether long-term estrogen replacement 
therapy would result in similar beneficial actions. 
Summary 
Estrogen has both short- and long-term effects on the 
cardiovascular system. Short-term estrogen administration in-
creases cardiac output predominantly through increases in 
heart rate, probably by a reflex response to systemic vasodila- 
tion. However, estrogen may also have a central effect or may 
have positive inotropic properties. Short-term coronary vaso- 
dilation may occur, but this is less well substantiated. In 
atherosclerotic arteries, a reversal of the paradoxic vasocon- 
strictive response to acetylcholine is seen, suggesting short- 
term potentiation ofendothelium-derived r laxing factor; this 
mechanism may also be important in long-term estrogen 
replacement. 
Long-term estrogen therapy has a highly beneficial effect on 
the lipid profile, with associated elevations in HDL cholesterol 
and apolipoprotein A-I levels and reductions in LDL choles- 
terol and lipoprotein(a) levels. There is also a modest increase 
in triglyceride levels of uncertain clinical significance. Im- 
proved vascular elasticity through reduced collagen synthesis 
and decreased tendency to myointimal hyperplasia lso appear 
to be long-term effects of estrogen therapy. Estrogen use may 
also result in increased prostacyclin production, with a result- 
ant inhibition of platelet aggregation as well as an increase in 
vasodilation. Although mild alterations in hemostatic factors 
occur, they do not appear, on balance, to be deleterious in 
usual clinical doses. Hemodynamically, ong-term estrogen 
replacement appears to increase cardiac output through an 
elevation of stroke volume, without a long-term effect on heart 
rate, This may be through normalization freduced intramyo- 
cardial calcium myosin ATPase and myosin isoenzymes. Blood 
pressure is minimally affected, if at all, but systemic vascular 
resistance decreases. 
Progesterone appears to attenuate slightly the beneficial 
effects of estrogen replacement on the lipid profile but may 
ameliorate the mildly hemostatic effects of estrogen by effect- 
ing a reduction in factor VII levels. Although the hemody- 
namic effects of combined estrogen and progesterone have not 
been as extensively studied as those of estrogen alone, proges- 
terone does not appear to modify substantially the changes 
seen with estrogen. 
A full discussion of the noncardiac risks and benefits of 
estrogen and combined estrogen and progesterone therapy is 
beyond the scope of this review. However, these risks and 
benefits have recently been reviewed by Grady et al. (76). For 
the clinician, it is important to recognize that although estro- 
gen replacement has been associated with a reduction in 
cardiovascular morbidity and mortality in nonrandomized tri- 
als, with plausible mechanisms for this effect having been 
demonstrated, large randomized trials have only recently been 
organized. Thus, a number of questions remain to be an- 
swered. Specifically, the questions of which patients to treat, 
when to start therapy and what regimen of estrogen and 
progesterone is most efficacious have not been completely 
answered by the available data. 
Importantly, estrogen therapy has been associated with 
reductions in cardiovascular disease in smokers as well as in 
nonsmokers (5); smoking, therefore, does not appear to be a 
reason to withhold therapy. The risk of inducing breast cancer 
appears to be small (76), but certain subgroups, such as 
patients with a family history of breast cancer, may be at higher 
risk. In general, a patient with a history of breast cancer is 
considered to have an absolute contraindication to estrogen 
therapy, although this remains controversial (77). Because of 
subtle changes in hemostasis, women with coagulation disor- 
ders may not be appropriate candidates for hormone replace- 
ment. The risk of estrogen therapy in a patient with hypertri- 
glyceridemia s not clear, nor is the risk of estrogen-induced 
hypertriglyceridemia. Although there are no known interac- 
tions of estrogen replacement with commonly used medica- 
tions, this issue has not been specifically addressed. Finally, the 
role of racial, ethnic and sociologic differences in response to 
therapy may be significant and requires further evaluation. 
The results of a number of recently organized ongoing trials 
are eagerly awaited. Until more concrete data are available, 
the decision to start postmenopausal hormone replacement 
must be based on the best information available for an 
individual patient, with careful discussion of the relative impli- 
cations of anticipated risks, benefits and life-style changes. 
Overall, cardiovascular disease is the number one killer of 
women in the United States, accounting for -33% of all deaths 
in women >50 years old. Particularly for women with docu- 
mented coronary artery disease or risk factors for its develop- 
ment, the available epidemiologic and physiologic data 
strongly support the hypothesis that estrogen replacement 
therapy significantly reduces the risk of cardiovascular morbid- 
ity and mortality. 
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